Royalty Pharma(US:RPRX) ZACKS·2026-02-10 15:15Core Insights - Royalty Pharma (RPRX) is expected to report quarterly earnings of $1.33 per share, reflecting a 15.7% increase year-over-year, with revenues projected at $824.89 million, an 11.2% increase from the previous year [1] Earnings Projections - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating stability in expectations [1] - The importance of earnings estimate revisions is highlighted as they are a critical gauge for predicting investor behavior [2] Key Metrics Projections - Analysts predict 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' will reach $230.74 million, a decrease of 2.6% year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is expected to reach $64.04 million, reflecting a 5% increase from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is projected at $41.09 million, indicating a 10.7% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is expected to reach $49.32 million, a 7.2% increase from the previous year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is projected at $22.16 million, showing a significant decrease of 49.6% year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is expected to reach $57.64 million, reflecting a 47.8% increase [6] - 'Portfolio Receipts- Milestones and other contractual receipts' is estimated at $11.40 million, a decrease of 12.4% year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is projected at $58.82 million, indicating a 5% increase [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is expected to reach $11.79 million, a 7.1% increase from the previous year [8] - The total for 'Portfolio Receipts- Royalty Receipts- Products' is projected at $813.50 million, reflecting an 11.6% increase year-over-year [8] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $93.70 million, indicating a 26.6% increase [9] - 'Portfolio Receipts- Royalty Receipts- Products- Spinraza' is projected at $13.37 million, suggesting a 10.9% decrease year-over-year [9] Stock Performance - Over the past month, shares of Royalty Pharma have returned +9.4%, while the Zacks S&P 500 composite has shown no change [9]